featured
Triple Combination of Interferon Beta-1b, Lopinavir–Ritonavir, and Ribavirin in the Treatment of Patients Admitted to the Hospital With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Triple Combination of Interferon Beta-1b, Lopinavir–Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial
Lancet 2020 May 08;[EPub Ahead of Print], IF Hung, KC Lung, EY Tso, R Liu, TW Chung, MY Chu, YY Ng, J Lo, J Chan, AR Tam, HP Shum, V Chan, AK Wu, KM Sin, WS Leung, WL Law, DC Lung, S Sin, P Yeung, CC Yip, RR Zhang, AY Fung, EY Yan, KH Leung, JD Ip, AW Chu, WM Chan, AC Ng, R Lee, K Fung, A Yeung, TC Wu, JW Chan, WW Yan, WM Chan, JF Chan, AK Lie, OT Tsang, VC Cheng, TL Que, CS Lau, KH Chan, KK To, KY YuenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.